Quantum Science Is Bolstering Production Capability by Expanding Into a 2nd Laboratory in Daresbury, Cheshire

The manufacturer of the groundbreaking INFIQ® quantum dot (QD) technology, Quantum Science, is bolstering its production capability by expanding into a second laboratory at its site in Daresbury, Cheshire.

Serving as a high-volume manufacturing facility, the new laboratory will feature specialist equipment including a highly precise automated reaction system, which will help Quantum Science upscale its production to serve millions of SWIR sensors each year.

The expansion follows a year of rapid development for Quantum Science that has seen it go from a small start-up to an established innovator in the QD industry operating in numerous international markets.

Quantum Science’s INFIQ® QDs are light-absorbing nanocrystals with significant applications for the sensing and imaging fields.

Existing technologies either cannot detect light in the short-wave infrared (SWIR) wavelength, or are prohibitively expensive, whereas INFIQ® QDs offer competitive performance at a mass-market price.

Widespread use of this technology will advance the semiconductor and electronics industries and unlock applications for sectors including medicine, defence, automation, and more.

Commenting on the expansion, Dr Hao Pang, CEO and Founder of Quantum Science, said: “Quantum Science has already demonstrated its technology and product leadership in the market, and now is the time for us to take the next step in our journey. This expansion into a second lab means we will not only be producing world leading QD technology, but we can also significantly upscale our operations to the point that our materials will be able to serve millions of SWIR quantum dot sensors worldwide.

“This growth will put Quantum Science in an unparalleled position to serve the current and rising global SWIR quantum dot device markets. It also highlights our commitment to our mission: providing the SWIR industry with the best quantum dot materials and technologies, enabling developers to bring high-performance and affordable SWIR sensing and imaging to life.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version